These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 27642030)

  • 1. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
    Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
    Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab.
    Choi JN
    Semin Cutan Med Surg; 2014 Mar; 33(1):40-8. PubMed ID: 25037257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
    Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I
    Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
    Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
    Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].
    Gutzmer R; Hassel JC; Kähler KC; Loquai C; Mössner R; Ugurel S; Zimmer L; der das Ado FK
    Hautarzt; 2014 Jul; 65(7):582-9. PubMed ID: 24903029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
    Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
    Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous toxicities of new treatments for melanoma.
    Boada A; Carrera C; Segura S; Collgros H; Pasquali P; Bodet D; Puig S; Malvehy J
    Clin Transl Oncol; 2018 Nov; 20(11):1373-1384. PubMed ID: 29799097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.